MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Matinas BioPharma Holdings, Inc.

1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States

Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Mr. Jerome D. Jabbour J.D.Co-Founder, CEO, Pres & Director450.46kN/A1974
Dr. Raphael J. ManninoSr. VP & Chief Scientific Officer240kN/A1947
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial OfficerN/AN/A1970
Dr. Theresa MatkovitsChief Devel. OfficerN/AN/A1967
Mr. Frank CalamusaExec. Director and Head of Manufacturing & Supply ChainN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides. The company's lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. In addition, it provides MAT2501, an orally administered cochleate formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with ViiV Healthcare for the treatment and care for people living with human immunodeficiency virus. The company was founded in 2013 and is based in Bedminster, New Jersey.

Corporate Governance

Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.